Drug Profile
Research programme: cancer vaccines - Hookipa Pharma
Alternative Names: artLCMV - Hookipa; HB-401Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Hookipa Biotech
- Developer Hookipa Pharma
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Malignant melanoma
Most Recent Events
- 05 Aug 2021 Pharmacodynamics data from a preclinical trial in malignant melanoma released by Hookipa Pharma
- 01 Aug 2021 Preclinical trials in Malignant melanoma in Austria (Parenteral) before August 2021
- 28 Dec 2020 No recent reports of development identified for preclinical development in Head-and-neck-cancer in Austria (IV)